Literature DB >> 25013466

Pathological characteristics of esophageal cancer.

Hong-Yun Shi1, Shu-Chai Zhu2, Wen-Bin Shen2, Miao-Ling Liu1.   

Abstract

The pathological characteristics of esophageal squamous cell carcinoma, which include regularly occurring multiple carcinogenic lesions (MLs), severe dysplasia (SD) and direct intramural infiltration (DI), were investigated using large pathological sections. A total of 52 esophageal cancer patients underwent surgical resection and were diagnosed with esophageal squamous cell carcinoma. Large sections of the surgical resection specimens were then made for pathological examination. The actual length of the carcinoma was calculated during surgery from the length determined microscopically. ML, SD and DI were identified during pathological examination of the large sections by microscope and were statistically analyzed. The lesion lengths obtained by the various inspection methods differed from each other. ML, SD and DI were identified in 15, 28 and 41 patients, respectively. Furthermore, a higher incidence of DI was observed in patients with lymphatic infiltration or those with a later stage of disease. ML, SD and DI were identified as characteristics of esophageal squamous cell carcinoma, and ML and DI were found to correlate with lymphatic infiltration.

Entities:  

Keywords:  esophageal squamous cell carcinoma; large pathological section; pathological characteristics; radiation; surgery

Year:  2014        PMID: 25013466      PMCID: PMC4081381          DOI: 10.3892/ol.2014.2223

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


Introduction

Approximately 482,300 novel cases and 406,800 mortalities from esophageal cancer (EC) are reported annually worldwide (1). EC is the sixth most common cause of cancer mortality. The incidence of EC in China accounts for 50% of cases worldwide, and the incidence of EC in Henan province is >100/100,000 individuals. Although surgery, radiotherapy, chemotherapy and biologically targeted therapies continue to progress, the five-year survival rate for early EC patients undergoing surgical treatment is ~30%. The reason for the majority of failures is due to tumor recurrence (2–4). In addition, the use of radiotherapy has been a focus of debate. Therefore, the aim of the present study was to investigate the pathological occurrence of squamous cell carcinoma by investigating the pathological features of esophageal squamous cell carcinoma using large sections. This may guide doctors to determine the clinical target volume of radiotherapy, achieve a treatment for cancer and reduce the radiation doses to the normal tissues in order to improve a patient’s quality of life following treatment.

Materials and methods

Clinical data

A total of 52 EC patients who underwent radical resection in the Fourth Hospital of Hebei Medical University (Shijiazhuang, China) between 2011 and 2012 were included in the present study according to the following inclusion criteria: Pre-operative lesion length on esophagography of >3 cm; complete chest computed tomography (CT) scan, abdominal ultrasound and conventional biochemical test records; and pathological confirmation of squamous cell carcinoma. The 52 EC patients consisted of 34 males (65.4%) and 18 females (34.6%), with a mean age of 59 years (range, 26–73 years). The lesions were identified in the upper thorax of six cases, the middle thorax of 40 cases and the lower thorax of six cases. Esophageal imaging X-rays revealed a mean lesion length of 5.8±1.4 cm (range, 3–10 cm). Three cases were stage T2 and 49 cases were stage T3, 28 cases were stage N0 and 24 cases were stage N1, and 51 cases were stage M0 and one case was stage M1. In addition, 29 cases were stage II, 22 cases were stage III and one case was stage IV. TNM staging was determined according to the Union for International Cancer Control (5). Patients provided written informed consent. The study was approved by the ethics committee of The Fourth Hospital of Hebei Medical University.

Detection methods and experimental procedure

The lesions and esophagus-related indicators were measured intraoperatively, and specimens were fixed for 24 h. The tumor length, invasion depth and the distances between the upper edge and the upper cutting edge of the tumor and between the lower edge and the lower cutting edge were measured without tension during surgery. The excised EC specimens were fixed with 10% formalin solution for 24 h, and the length of the specimens and invasion depths were measured. The types of tumor were identified and recorded. To produce the large sections for pathological examination, 10% formaldehyde solution was used to fix specimens for >24 h, and two 0.3-cm wide tissue blocks were obtained from the fixed specimens. The tissue blocks contained the longest longitudinal section and both sides of the excised esophagus. Gauze (20 mesh) was used to produce the tissue boxes to avoid any distortion in the process of section production. Following dehydration, embedding, sectioning, staining, dehydration transparency and cementing, the large pathological sections were completed. For the diagnosis and measurement of the associated indicators, the sections were observed under a microscope to identify the occurrence of multiple carcinogenic lesions (MLs), severe dysplasia (SD), direct intramural infiltration (DI) (Fig. 1), lymph node metastasis, vascular invasion and lymphatic invasion.
Figure 1

Equipment used to produce the large sections for pathological examination, and diagram of retraction during surgery.(A) Paraffin-embedded specimens of esophageal cancer, (B) a homemade tissue box and (C) a slicing knife. (D) Diagram of retraction during surgery (L1, normal esophagus above the esophageal tumor and A1, distance between ML and main tumor prior to surgery) and of the large sections (L2, normal esophagus above the esophageal tumor and A2, the distance between ML and main tumor following surgery). Red presents the main tumor and black the ML. L1/L2 = A1/A2. This equation allows the distance between the ML and the main tumor in the patient prior to the operation to be calculated. ML, multiple carcinogenic lesion.

The diagnostic criteria were as follows: ML, foci separated from the main tumor exhibiting characteristics of atypical hyperplasia carcinoma in situ or invasive carcinoma; SD, undifferentiated atypical cells accounting for >2/3 of the esophageal epithelial cell layer without breaking through the underlying membrane; and DI, normal mucosal epithelial lining of the esophagus with cancer submucosal infiltration or myometrial invasion. The actual length of the carcinomas were calculated from the length determined microscopically, using the following equation: L1/L2 = A1/A2 where L1 is the length of the normal esophagus above the esophageal tumor and A1 is the distance between ML and main tumor prior to surgery. L2 is the normal esophagus above the esophageal tumor and A2 is the distance between ML and main tumor following surgery. Using this equation the distance between the ML and the main tumor in the patient prior to the operation may be calculated. All other actual lengths were calculated using the same method (Fig. 2).
Figure 2

Large pathological section. (A) Unaided view and endoscopic views of the (B) multiple carcinogenic lesion (ML), (C) severe dysplasia (SD), (D) direct intramural infiltration (DI) and (E) lymphatic invasion.

Statistical analysis

Statistical analyses were conducted using SPSS version 11.5 (SPSS, Inc., Chicago, IL, USA) and data are presented as the mean ± standard deviation. The means of the two groups were compared by t-test, and the means of multiple groups were compared by analysis of variance and χ2 test. Correlations between the pathological features were analyzed by the Pearson’s correlation test. P<0.05 was considered to indicate a statistically significant difference.

Results

Comparison of lesion lengths

The comparison between lesion lengths determined by esophagography, esophagoscopy and CT scan, and those measured during surgery are shown in Table I. The mean lesion length determined by esophagoscopy was 5.20±1.64 cm, which was significantly different (P=0.004) from the mean lesion length observed during surgery (5.83±1.41 cm). Esophageal stenosis, which inhibits esophagoscopy, may account for this. The lesion lengths determined by CT scan were the largest. This may be associated with the thickening of the esophageal lumen due to esophageal edema around the EC.
Table I

Comparison between tumor lengths measured during surgery and other methods.

Measuring methodMean, cmT-valueP-value
Surgery5.83±1.41
Esophagography5.51±1.462.4950.016
Esophagoscopy5.20±1.643.0560.004
CT scan6.30±2.812.0640.042

CT, computed tomography.

Vascular tumor emboli and lymphatic invasion

Vascular tumor emboli were identified in six out of 52 patients, accounting for 11.5% of the total number of patients. Statistical analysis was not performed, as only six cases were identified. In addition, lymphatic invasion was observed in 36 out of 52 patients, accounting for 69.2% of the total number of patients.

Distribution and factors affecting ML

A total of 28.8% of the patients (15 out of 52) were found to exhibit ML, with seven cases identified at the proximal end (upper) of the section, three cases at the distal end (lower) and five cases at both ends. The mean proximal distance between the ML and the main tumor, in addition to the length of the ML was 3.02±1.45 cm (largest length, 5.0 cm). In 95% of patients, a distance of <5.0 cm was exhibited, while 90% of patients exhibited a distance of <4.5 cm. The mean distal distance between the ML and the main tumor, in addition to the length of the ML was 2.60±2.44 cm (largest length, 7.5 cm). In 95% of patients, a distance of <7.5 cm was exhibited, while 90% of patients exhibited a distance <5.0 cm. No significant difference was identified between the mean proximal and mean distal distances (P=0.633; Table II).
Table II

Distances between the subclinical lesion and the main tumor in addition to the subclinical lesion itself.

Subclinical lesionMaximum, cmMean, cma95% CI, cm90% CI, cmT-valueP-value
ML
 Proximal end5.03.02±1.45≤5.0≤4.50.4860.633
 Distal end7.52.60±2.44≤7.5≤5.0
SD
 Proximal end5.02.45±1.30≤4.5≤3.81.2320.229
 Distal end6.253.24±2.18≤6.0≤5.0
DI
 Proximal end6.42.80±1.52≤5.0≤4.72.0120.049
 Distal end6.02.02±1.51≤4.8≤3.9

Data are presented as the mean ± standard deviation.

CI, confidence interval; ML, multiple carcinogenic lesion; SD, severe dysplasia; DI, direct intramural infiltration.

The lesion length and invasion depth were reduced in the patients with ML compared with the patients without ML (P=0.039 and 0.028, respectively), however, no significant difference was identified in the tumor volume between the two groups (Table III). Lymphatic invasion was identified in 36 cases and of these, 14 were found to exhibit ML, accounting for 38.9%, whereas only one patient was identified with ML from the 16 patients without lymphatic invasion (6.3%). A statistically significant difference was identified between the two groups (P=0.036). However, no significant correlation was identified between the ML, type of primary tumor, lesion position, N stage and TNM stage (Table IV).
Table III

Correlation between the subclinical lesions and local tumor factors.

Subclinical lesionTumor lengthTumor invasionTumor volume



Mean, cmaT-valueP-valueMean, cmaT-valueP-valueMean, cm3aT-valueP-value
ML
 Yes4.46±1.152.1250.0392.95±0.532.2620.02826.83±11.840.9290.357
 No5.49±1.733.35±0.5933.27±10.59
SD
 Yes5.64±1.100.9840.3313.54±1.140.8070.42329.02±14.240.9000.373
 No6.04±1.713.79±1.1432.94±17.20
DI
 Yes5.80±1.500.2160.8303.77±1.132.0400.04730.03±16.380.7080.482
 No5.91±1.043.00±0.8933.81±12.75

Data are presented as the mean ± standard deviation.

ML, multiple carcinogenic lesion; SD, severe dysplasia; DI, direct intramural infiltration.

Table IV

Factors affecting the subclinical lesions.

MLSDDI



FactorsNo, nYes, nχ2P-valueNo, nYes, nχ2P-valueNo, nYes, nχ2P-value
Lesion position1.210.5390.090.9470.620.780
 Upper esophagus513314
 Middle esophagus25111620631
 Lower esophagus513324
Lymphatic invasion4.150.0380.180.6754.120.043
 Yes20121518530
 No1517858
N stage3.420.0570.430.6911.820.183
 N02141119421
 N1149117516
TNM stage2.090.1350.140.718
 II21513147193.730.050
 III + IV148912220

ML, multiple carcinogenic lesion; SD, severe dysplasia; DI, direct intramural infiltration.

Distribution and factors affecting SD

A total of 53.8% of patients (28 out of 52) were found to exhibit SD, with 11 cases identified at the proximal end of the section, 11 cases at the distal end and six cases at both ends. The mean proximal distance between the SD and the main tumor, in addition to the length of the SD was 2.45±1.30 cm. The mean distal distance between the SD and the main tumor, in addition to the length of the SD was 3.24±2.18 cm. No significant difference was identified between the mean proximal and mean distal distances (P=0.229; Table II). In addition, no significant correlation was identified between the lesion length, invasion depth and tumor volume and the SD (Table III), or between the SD and the type of primary tumor, lymphatic invasion, lesion position, N stage and TNM stage (Table IV).

Distribution and factors affecting DI

A total of 78.8% of patients (41 out of 52) were found to exhibit DI, with 12 cases identified at the proximal end of the section, 10 cases at the distal end and 19 cases at both ends. The mean proximal distance between the DI and the main tumor, in addition to the length of the DI was 2.80±1.52 cm (largest length, 6.4 cm). The mean distal distance between the DI and the main tumor, in addition to the length of the DI was 2.02±1.51 cm (largest length, 6.0 cm). The mean proximal distance was significantly larger than the mean distal distance (P=0.049; Table II). In addition, the invasion depths were larger in patients with DI when compared with that of patients without DI (P=0.047). No significant correlation was identified between the lesion length, and tumor volume and the DI (Table III). However, a significant correlation was identified between lymphatic invasion and TNM stage (P=0.044) and the DI (P=0.05). No significant correlation was identified between the tumor volume and lesion position and the N stage (Table IV).

Discussion

Two hypotheses exist with regard to EC patients with ML (6,7); one proposes that EC evolved from a monoclonal cell, whereas the other hypothesizes that EC has a polyclonal origin. The reported incidence of EC patients with ML is 0.8%–10.8% (8). In the current study, the incidence of ML was 28.8%, which is markedly higher than the reported incidence in the literature. This may be due to the large sections used for pathological examination, which provide more information with regard to the tumor. It was also revealed that smaller tumors were found to correlate with a higher incidence of ML. This indicated that under the effect of the same outside carcinogenic factors, a fragment of normal esophageal tissue may exhibit atypical hyperplasia in multiple sites. This atypical hyperplasia may develop from mild to moderate hyperplasia, severe hyperplasia, carcinoma in situ or invasive carcinoma. The small foci of these different sites gradually grow and fuse into visible tumors, which induce clinical symptoms, including swallowing difficulty and hiccups. The incidence of ML is decreased when these multicarcinoma in situ or microinvasive carcinomas merge with each other. This may explain why certain pathologists have identified >8 ML in early EC (9). In the current study, the proportion of ML in patients with lymphatic invasion was identified to be larger than that of patients without lymphatic invasion, indicating that ML occurs simultaneously under the same pathogenic factors. An additional possibility is that cancer cells have migrated along the longitudinal lymphatics and settled at a certain point, and proliferation started from there. In the current study, the incidence of SD was 53.8%. Epidemiological studies have shown that the incidence of EC requires a continuous spectrum evolution, i.e., esophageal squamous epithelium, mild atypical hyperplasia, moderate atypical hyperplasia, SD, carcinoma in situ and invasive carcinoma (10,11). Much focus has been applied to SD, which exhibits undifferentiated atypical cells that account for >2/3 of the esophageal epithelial cell layer, but do not break through the underlying membrane. Carcinoma in situ refers to cancerized epithelial layers, which do not break through the basement membrane or infiltrate downward. Tao and Zong (12) analyzed EC specimens and found that the p53-positive and SD rates in carcinoma in situ were 98 and 79%, respectively (P>0.05). Although the specimens of the two groups exhibited different clinical stages, no differences in SD or p53 protein expression in carcinoma in situ were identified, indicating that SD has a carcinomic nature. Therefore, the current study also observed the occurrence of SD and summarized its characteristics. DI and lymphatic invasion have been identified in EC, which has the biological behavior of infiltrating along the esophageal mucosa or spreading to the upper esophagus in lesions of ≤10 cm in size (13). Compared with solid tumors from other areas, EC exhibits a longer diffusion distance, as the cancer cells infiltrate the esophageal wall and spread to the surrounding tissue. Notably, cancer cells can infiltrate along the lymphatics in the lower lamina propria, and occasionally cause nodular mucosal surface uplift. However, in the majority of cases, no evident abnormalities are identified and confirmation by microscope is required. This diffusion may be identified 5 or even >10 cm away from the primary tumor range, according to the published data. The majority of the literature supports the hypothesis that the diffusion distance to the upper end is larger than that to the lower end (13), which was also confirmed in the current study. Although large sections for pathological study have a long production period, the entire tumor is included, as well as the proximal and distal resected tissues. The end results also have more integrity and continuity, and are excellent for investigating the associations between tumors and their surrounding tissues. In conclusion, esophageal squamous cell carcinoma exhibits the characteristics of ML, SD and DI, and the occurrence of ML and SD has been associated with lymphatic invasion. In 95% of the subclinical lesions observed in the current study, the proximal distance was 5.0 cm and the distal distance was 7.5 cm, while in 90% of the subclinical lesions, the proximal distance was 4.7 cm and the distal distance was 5.0 cm. Further information may be obtained by future investigations of the pathological characteristics of EC, which could be used to identify a potential breakthrough in cancer research to relieve the suffering of patients, while reducing normal tissue damage and maximally improving quality of life.
  7 in total

1.  Details of recurrence sites after elective nodal irradiation (ENI) using 3D-conformal radiotherapy (3D-CRT) combined with chemotherapy for thoracic esophageal squamous cell carcinoma--a retrospective analysis.

Authors:  Hideomi Yamashita; Kae Okuma; Reiko Wakui; Shino Kobayashi-Shibata; Kuni Ohtomo; Keiichi Nakagawa
Journal:  Radiother Oncol       Date:  2010-11-11       Impact factor: 6.280

2.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

3.  Field cancerization in the aerodigestive tract--its etiology, manifestation, and significance.

Authors:  M S Strong; J Incze; C W Vaughan
Journal:  J Otolaryngol       Date:  1984-02

4.  Long-term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell neoplasms.

Authors:  Satoshi Ono; Mitsuhiro Fujishiro; Keiko Niimi; Osamu Goto; Shinya Kodashima; Nobutake Yamamichi; Masao Omata
Journal:  Gastrointest Endosc       Date:  2009-07-04       Impact factor: 9.427

5.  p53 protein accumulation and gene mutations in multifocal esophageal precancerous lesions from symptom free subjects in a high incidence area for esophageal carcinoma in Henan, China.

Authors:  L D Wang; Q Zhou; J Y Hong; S L Qiu; C S Yang
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

6.  A randomized double-blind intervention study on the effect of calcium supplementation on esophageal precancerous lesions in a high-risk population in China.

Authors:  L D Wang; S L Qiu; G R Yang; M Lipkin; H L Newmark; C S Yang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1993 Jan-Feb       Impact factor: 4.254

7.  Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial.

Authors:  Jurjen J Boonstra; Tjebbe C Kok; Bas Pl Wijnhoven; Mark van Heijl; Mark I van Berge Henegouwen; Fiebo Jw Ten Kate; Peter D Siersema; Winand Nm Dinjens; Jan Jb van Lanschot; Hugo W Tilanus; Ate van der Gaast
Journal:  BMC Cancer       Date:  2011-05-19       Impact factor: 4.430

  7 in total
  4 in total

1.  Prognostic value of cancer stem cell marker CD133 expression in esophageal carcinoma: A meta-analysis.

Authors:  Yun-Peng Sui; Xue-Ping Jian; L I Ma; Gui-Zhen Xu; Huai-Wei Liao; Yan-Ping Liu; Hui-Cai Wen
Journal:  Mol Clin Oncol       Date:  2015-10-07

2.  Clinical significance of ALDH1 combined with DAPI expression in patients with esophageal carcinoma.

Authors:  Hong Chen; Zhi-Qiang Zhang; Bin Zhao; Wen-Long Ning; Xue-Yan Wang; Fei Zhou
Journal:  Oncol Lett       Date:  2017-08-10       Impact factor: 2.967

3.  Epigenetics in the Pathogenesis of Esophageal Adenocarcinoma.

Authors:  Aparna Kailasam; Sumeet K Mittal; Devendra K Agrawal
Journal:  Clin Transl Sci       Date:  2014-11-12       Impact factor: 4.689

4.  TM4SF1 promotes the self-renewal of esophageal cancer stem-like cells and is regulated by miR-141.

Authors:  Lei Xue; Xiying Yu; Xingran Jiang; Xin Deng; Linlin Mao; Liping Guo; Jinhu Fan; Qinqxia Fan; Liuxing Wang; Shih-Hsin Lu
Journal:  Oncotarget       Date:  2017-03-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.